
In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

A study reveals significant disparities in access to CAR T therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes.

A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.

Discover the latest breakthroughs in oncology, including innovative treatments and FDA approvals that enhance patient care and outcomes in cancer therapy.

A phase 2 trial reveals that ONO-4578 and nivolumab significantly extend progression-free survival in advanced gastric cancer patients.

During a live event, Michael J. Overman, MD, discussed biomarker testing, ctDNA, and later-line treatment options for metastatic colorectal cancer.

FDA fast tracks ADCE-D01, a promising treatment for soft tissue sarcoma, aiming to expedite patient access and improve survival rates.

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming treatment options for patients.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.

The FDA fast-tracks WTX-124, a promising therapy for advanced melanoma, aiming to improve treatment options for patients with limited choices.

A recent study reveals that systematic mediastinal lymph node dissection is unnecessary for stage T1 GGO-dominant lung adenocarcinoma, enhancing patient outcomes.

New findings from the SUNMO study highlight the promising efficacy and safety of Mosun-Pola for treating relapsed large B-cell lymphoma, offering a chemotherapy-free option.

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

Long-term study reveals active surveillance is a safe management strategy for low-risk papillary thyroid cancer, especially in older patients.

The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma.

A new drug application for Dasynoc was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

A phase 1 study reveals promising safety and efficacy of NBTXR3 combined with radiotherapy and immunotherapy for resistant melanoma patients.

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods.

A new study reveals casdatifan's promising efficacy in treating late-stage kidney cancer, showing significant progression-free survival and response rates.

A phase 2 study reveals low-dose nivolumab and lenalidomide as a promising, safe, chemotherapy-free treatment for classical Hodgkin lymphoma.

Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.

CAR T-cell therapy for DLBCL shows promise in outpatient settings, reducing hospital stays and improving patient quality of life while managing toxicities effectively.

Datopotamab deruxtecan has shown significant survival benefits in patients with metastatic triple-negative breast cancer, marking a potential breakthrough in therapy options.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

A new study reveals that multiple tattoos may lower melanoma risk, challenging previous beliefs about tattooing and skin cancer.

The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.

Ziftomenib shows promising results in treating relapsed/refractory acute myeloid leukemia with NPM1 mutations, offering hope for improved patient outcomes.